STOCK TITAN
  1. Home
  2. News
  3. INAB

IN8bio, Inc. - INAB STOCK NEWS

Welcome to our dedicated page for IN8bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio stock.

IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of novel therapies aimed at treating various cancers. Using allogeneic, autologous, and genetically modified gamma-delta T cells, IN8bio is revolutionizing cancer treatment. The company’s mission is to create groundbreaking therapies that harness the power of the body’s immune system to target and destroy cancer cells.

IN8bio's robust portfolio includes several promising product candidates:

  • INB-400: Aimed at treating newly diagnosed glioblastoma (GBM), this product is currently in a Phase 2 clinical trial.
  • INB-100: Designed for patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, this therapy is under Phase 1 clinical trials.
  • INB-200: Another promising candidate targeting GBM, it has shown encouraging preliminary clinical data at the 2024 ASCO Annual Meeting.
  • Additional products, like INB-300 and INB-500, are in various stages of development targeting both solid and liquid tumors.

Recently, IN8bio disclosed significant advancements in the treatment of GBM, utilizing their innovative gamma-delta T cell-based adoptive cellular therapy. A peer-reviewed publication highlighted the strategy and future direction of their novel treatment methods.

Financially, IN8bio extends its cash runway into 2025, bolstered by additional capital from a private placement in December 2023. The company continues to pursue more funding to advance its clinical trials and achieve its milestones.

IN8bio's groundbreaking work has garnered attention in the biotech field, especially for its genetically modified gamma-delta T cells, which are the first to be advanced into clinical trials. The company’s approach shows great potential in improving progression-free survival (PFS) and overall survival (OS) rates for GBM and other cancers.

For investors and stakeholders, IN8bio provides exciting opportunities as it moves towards commercializing its therapies, aiming to address significant unmet medical needs in oncology. For more information, please visit IN8bio.

News

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) will present 'late-breaker' and Trials-in-Progress (TIPs) posters at the Society for Neuro-Oncology (SNO) 28th Annual Meeting. The posters will showcase updated clinical data from the Phase 1 trial of INB-200 and details of the company-sponsored Phase 2 trial of INB-400, highlighting the potential of genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences
-
News

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) announced the completion of dose escalation in Phase 1 Trial of INB-100 and INB-200, with updated clinical data to be presented at ASH and SNO Annual Meetings. The company also initiated enrollment for Phase 2 trial of INB-400 in newly diagnosed GBM. The PR highlights positive clinical and scientific programs and multiple upcoming catalysts, including significant financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
earnings
-
News

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Rhea-AI Summary
IN8bio, Inc. presents new biological correlative data from the ongoing Phase 1 clinical trial of INB-200, a gamma-delta T cell therapy targeting glioblastoma multiforme (GBM). The data demonstrate the ability of single and repeat doses of INB-200 to induce T cell persistence and a sustained immune response. A treated patient showed infiltration of gamma-delta T cells 148 days after a single administration. Updated patient, survival, and enrollment data will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting on November 17, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Rhea-AI Summary
IN8bio, Inc. presented positive preclinical data on its iPSC gamma-delta T cell platform at the SITC Annual Meeting. The company's proprietary expansion methods can produce billions of iVδ1 T cells with low risk of cytokine release syndrome. The platform enables the differentiation into both Vd1+ and Vd2+ cell subtypes and has shown strong cancer-killing abilities against various solid and liquid cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
News

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary
IN8bio, Inc. announces positive data from the Phase 1 trial of INB-100 in patients with hematologic malignancies. The trial shows promising efficacy, a favorable safety profile, and evidence of robust gamma-delta T cell expansion. The data will be presented at the 65th American Society of Hematology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
conferences clinical trial
-
News

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will participate in 1x1 meetings at the Truist Securities BioPharma Symposium. The company expects multiple data updates through year-end 2023 at upcoming industry events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

Rhea-AI Summary
Enrollment is now open in the Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase of the investigator-sponsored trial of INB-100 in leukemia patients. R&D Day held today. IN8bio, Inc. announced the completion of enrollment in the Phase 1 study of INB-100 in leukemia patients and the initiation of patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
clinical trial
-
News

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

Rhea-AI Summary
IN8bio, Inc. announced positive data presentations at the SITC Annual Meeting, showcasing Phase 1 trial results for INB-200 and pre-clinical insights on their iPSC gamma-delta T cell platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
none
-
News

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

Rhea-AI Summary
IN8bio, Inc. announces its upcoming Research & Development Day on October 12, 2023, featuring presentations by clinical thought leaders and upcoming data releases at fall medical meetings. The event will provide insights into IN8bio's clinical and scientific programs, including gamma-delta T cell therapies. Positive impact on stock price expected from potential catalysts and key opinion leader support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
conferences
News

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Rhea-AI Summary
IN8bio, Inc. CEO to participate in panel presentation at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.62%
Tags
conferences

FAQ

What is the current stock price of IN8bio (INAB)?

The current stock price of IN8bio (INAB) is $0.3176 as of November 22, 2024.

What is the market cap of IN8bio (INAB)?

The market cap of IN8bio (INAB) is approximately 23.2M.

What does IN8bio, Inc. do?

IN8bio, Inc. is a biotechnology company focused on developing novel cancer therapies using allogeneic, autologous, and genetically modified gamma-delta T cells.

What are the main products of IN8bio?

IN8bio's main products include INB-400 for glioblastoma, INB-100 for high-risk leukemias, and other candidates like INB-200, INB-300, and INB-500.

What recent advancements has IN8bio made?

IN8bio recently highlighted advancements in GBM treatment using gamma-delta T cell-based adoptive cellular therapy, showing promising clinical data at the 2024 ASCO Annual Meeting.

How is IN8bio funded?

IN8bio’s operations are funded through private placements and capital investments, extending their financial runway into 2025.

What is the significance of IN8bio's gamma-delta T cells?

IN8bio's gamma-delta T cells are the first genetically modified cells advanced into clinical trials, showing potential in improving cancer treatment outcomes.

How can I learn more about IN8bio’s clinical trials?

Details about IN8bio’s clinical trials can be found on their website and clinical trial registries like clinicaltrials.gov.

What is INB-400?

INB-400 is a Phase 2 clinical trial product targeting newly diagnosed glioblastoma, showing promising preliminary data in extending progression-free survival.

Where is IN8bio headquartered?

IN8bio, Inc. is headquartered in New York, NY.

Who can I contact for investor relations?

For investor relations, contact Lee M. Stern at Meru Advisors via email at lstern@meruadvisors.com.

How does IN8bio contribute to cancer research?

IN8bio contributes by developing cutting-edge therapies that leverage the body's immune system to target cancer cells, advancing both scientific and clinical understanding of gamma-delta T cell functions.

Stock INAB logo
IN8bio, Inc.

Nasdaq:INAB

INAB Rankings

#5228 Ranked by Market Cap
N/A Ranked by Dividends

INAB Stock Data

23.24M
55.10M
21.56%
46.46%
1.38%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK